Who is sponsoring NCT05148039?

NCT05148039 is sponsored by Queen Mary University of London.

What drugs are being tested in NCT05148039?

Interventions in NCT05148039: Dietician advice.

What condition does NCT05148039 study?

NCT05148039 studies Hypermobile Ehlers-Danlos Syndrome, Irritable Bowel Syndrome, Functional Gastrointestinal Disorders.

Is NCT05148039 still recruiting?

NCT05148039 is currently completed. Last updated 7 August 2023.

Last reviewed 2023-08-07 · How we verify

NCT05148039: CANDI-hEDS2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comprehensive Assessment of Nutrition and Dietary Intervention in Hypermobile Ehlers Danlos Syndrome

Completed NA Last updated 7 August 2023

What this trial tests

NA trial testing Dietician advice in Hypermobile Ehlers-Danlos Syndrome in 50 participants. Completed in 3 July 2023.

Timeline

7 April 2022

Primary endpoint
3 July 2023

3 July 2023

Quick facts

Lead sponsor	Queen Mary University of London
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	50
Start date	7 April 2022
Primary completion	3 July 2023
Estimated completion	3 July 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

Dietician advice

Conditions studied

Hypermobile Ehlers-Danlos Syndrome — all drugs for Hypermobile Ehlers-Danlos Syndrome →
Irritable Bowel Syndrome — all drugs for Irritable Bowel Syndrome →
Functional Gastrointestinal Disorders — all drugs for Functional Gastrointestinal Disorders →

Sponsor

Queen Mary University of London

Who can join

16 and older, any sex, with Hypermobile Ehlers-Danlos Syndrome or Irritable Bowel Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study involves a comprehensive nutritional assessment of hEDS participants who have functional gastrointestinal disorders and dietary intervention to broaden their food choices and nutritional intake.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Hypermobile Ehlers-Danlos Syndrome

Currently open trials in the same condition.

NCT05212129 — Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome · NA · recruiting

Other Queen Mary University of London trials

Trials by the same sponsor.

NCT07246005 — LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus · Phase 2 · not yet recruiting
NCT07165678 — CTCA Prior to Invasive Angiography in Post-Bypass Patients (BYPASS CTCA 2) · NA · not yet recruiting
NCT06937372 — Delivery and Implementation of a Randomised Crossover Trial on Thrombosis · NA · not yet recruiting
NCT06600438 — Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial · NA · not yet recruiting
NCT06987045 — Trans and Non-binary Prostate-Specific Antigen Reference Interval Determination Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05148039 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Queen Mary University of London
Last refreshed: 7 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05148039.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing